April 14, 2012

Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer

Several randomized controlled trials have shown lower rates of non-melanoma skin cancer among patients who receive sirolimus from the time of transplant. This study randomized previously transplanted patients who had previously had at least one skin cancer to either continue on their usual immunosuppression or change their calcineurin inhibitor to sirolimus. There were fewer new skin cancers in the sirolimus group and suggests a possible strategy to reduce this complication in patients at high risk post-transplant.